The EVIDENCE Study set out to test the cost-effectiveness of subcutaneous interferon against the intramuscular dose in the treatment of relapsing forms of multiple sclerosis. The results were presented at the AMCP meeting. See more here. (Source: Eileen Koutnik, First Report Managed Care, 11/14/14)
You are here: / / Interferon For MS – Is It Cost-Effective?